Healthcare Stocks Move in Pre-Market Session: Gainers and Losers
ByAinvest
Thursday, Jul 10, 2025 1:27 pm ET1min read
BMGL--
The pre-market activity in Cognition Therapeutics (CGTX) was likely driven by the company's recent FDA meeting for its Alzheimer's drug candidate zervimesine. The company completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, which focused on reviewing results from the Phase 2 "SHINE" study and discussing plans for a Phase 3 program [2]. The SHINE study met its primary endpoints of safety and tolerability, and the company expects to receive formal minutes from the FDA in August. This positive development may have contributed to the significant gain in the pre-market session.
Klotho Neurosciences (KLTO) and IGC Pharma (IGC) also saw gains, although the specific catalysts for their movements were not detailed in the provided materials. ProKidney (PROK) experienced a notable increase, but no specific information was provided for this stock.
On the losing side, Mereo BioPharma Group (MREO) and Creative Medical Tech (CELZ) were among the biggest decliners, with losses of up to 31%. Ultragenyx Pharmaceutical (RARE) and Basel Medical Group (BMGL) also experienced significant declines. The reasons for these losses were not specified in the provided materials.
Pre-market trading can often indicate important events that have occurred or are happening in the stock market. Stocks trading in early morning hours are usually reacting to recent news events and company-specific announcements [1]. The large price changes and volume that significantly exceed the normal range are notable indicators of pre-market activity [1].
Investors should closely monitor these companies for any upcoming announcements or earnings reports that may influence their stock prices. The pre-market activity provides a glimpse into the market's initial reaction to news events, but it is essential to consider the full context and fundamentals of each company before making investment decisions.
References:
[1] https://marketchameleon.com/Reports/PremarketTrading
[2] https://ca.investing.com/news/company-news/cognition-therapeutics-completes-fda-endofphase-2-meeting-for-alzheimers-drug-93CH-4096614
CELZ--
CGTX--
IGC--
KLTO--
Healthcare stocks moving in Thursday's pre-market session include Cognition Therapeutics CGTX, Klotho Neurosciences KLTO, IGC Pharma IGC, and ProKidney PROK, with gains of up to 45.7%. Losers include Mereo BioPharma Group MREO, Creative Medical Tech CELZ, Ultragenyx Pharmaceutical RARE, and Basel Medical Group BMGL, with declines of up to 31%.
Healthcare stocks experienced significant movement in Thursday's pre-market session, with several companies showing notable gains and losses. Cognition Therapeutics (CGTX) led the pack with a gain of up to 45.7%, followed by Klotho Neurosciences (KLTO), IGC Pharma (IGC), and ProKidney (PROK) [1]. Meanwhile, losers included Mereo BioPharma Group (MREO), Creative Medical Tech (CELZ), Ultragenyx Pharmaceutical (RARE), and Basel Medical Group (BMGL) [1], with declines of up to 31%.The pre-market activity in Cognition Therapeutics (CGTX) was likely driven by the company's recent FDA meeting for its Alzheimer's drug candidate zervimesine. The company completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, which focused on reviewing results from the Phase 2 "SHINE" study and discussing plans for a Phase 3 program [2]. The SHINE study met its primary endpoints of safety and tolerability, and the company expects to receive formal minutes from the FDA in August. This positive development may have contributed to the significant gain in the pre-market session.
Klotho Neurosciences (KLTO) and IGC Pharma (IGC) also saw gains, although the specific catalysts for their movements were not detailed in the provided materials. ProKidney (PROK) experienced a notable increase, but no specific information was provided for this stock.
On the losing side, Mereo BioPharma Group (MREO) and Creative Medical Tech (CELZ) were among the biggest decliners, with losses of up to 31%. Ultragenyx Pharmaceutical (RARE) and Basel Medical Group (BMGL) also experienced significant declines. The reasons for these losses were not specified in the provided materials.
Pre-market trading can often indicate important events that have occurred or are happening in the stock market. Stocks trading in early morning hours are usually reacting to recent news events and company-specific announcements [1]. The large price changes and volume that significantly exceed the normal range are notable indicators of pre-market activity [1].
Investors should closely monitor these companies for any upcoming announcements or earnings reports that may influence their stock prices. The pre-market activity provides a glimpse into the market's initial reaction to news events, but it is essential to consider the full context and fundamentals of each company before making investment decisions.
References:
[1] https://marketchameleon.com/Reports/PremarketTrading
[2] https://ca.investing.com/news/company-news/cognition-therapeutics-completes-fda-endofphase-2-meeting-for-alzheimers-drug-93CH-4096614

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet